Navigation Links
Audax Medical, Inc. Secures Exclusive Rights to Novel Osteobiologic Nanotechnology

LITTLETON, Mass., Dec. 7, 2010 /PRNewswire/ -- Audax Medical, Inc. (, a privately-held medical device company specializing in the development of osteobiologics, has entered into a comprehensive license agreement with Brown University, acquiring exclusive rights to a proprietary osteobiologic nanotechnology. The biomaterial, Arxis™, is being developed for use in multiple clinical applications for the regeneration of diseased bone, cartilage, and other soft tissues.  

An additional research agreement has been completed with the Brown University School of Engineering and Department of Orthopedics to further support clinical development of the technology.

"Our partnership with Brown and the University's world-class scientific team is a significant milestone for Audax Medical," stated Mark A. Johanson, President and Chief Executive Officer.  "The addition of this technology to the company's product portfolio greatly expands our growing regenerative osteobiologics and soft tissue platforms."

Under the terms of the agreement, Audax Medical has obtained exclusive license to a platform of intellectual property and technologies co-developed by Thomas Webster, Brown professor of engineering, addressing the treatment of degenerative bone and soft tissues.

"We are very excited to have partnered with such an experienced and accomplished team at Audax Medical," stated Katherine Gordon, Managing Director of the Brown University Technology Ventures Office. "The scientific and commercial expertise from both the Brown and Audax teams are impressive, offering a significant opportunity for both clinical and commercial success."

The Arxis™ biomaterial consists of organic nanomolecules which have the potential to meet an array of clinical needs. The implantable material can incorporate varying growth agents that allow its end characteristics to be customized for multiple clinical and regenerative indications throughout the musculoskeletal system.

More information about the science behind the technology, including pictures and video, can be found at

About Audax Medical, Inc.

Audax Medical, Inc. is a privately held medical device company located in Littleton, Massachusetts. The company offers innovative solutions for the treatment of degenerative bone and musculoskeletal tissue. The company's products go beyond simply stabilizing a clinical deficiency by promoting the growth of natural bone and tissue. With enhanced surgical based solutions and osteogenic biomaterial technologies, Audax offers a modern alternative to existing orthopedic therapies.  For more information visit,

SOURCE Audax Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prescient Medical, Inc. Presenting at the 5th Annual Canaccord Genuity Cardiovascular Conference
2. Cayenne Medical, Inc. Reaches 50,000 Implant Milestone
3. A Platform Technology to Address Bioterrorism Released by Aethlon Medical, Inc.
4. China Medical Technologies Announces its Subsidiary, GP Medical, Ranked Sixth in Deloitte Technology Fast 50 China 2010 Program
5. China Sky One Medical, Inc. Reports Outcome of Annual Meeting of Shareholders
6. Nonin Medical, Inc. Announces Capnography Division Name Change; Expands Swedish Manufacturing Facility to Become Full-Franchise European Sales, Distribution and Service Center
7. CSA Medical, Inc. Announces 75th Customer
8. Len DeBenedictis Retires as Chief Technology Officer of Solta Medical, Inc.
9. BlueDot Medical, Inc. Named to 2010 Inc. 500/5000
10. BINDER BIOMEDICAL, INC. Announces Official Launch of the NEWTON™ Intervertebral Body Fusion Spinal Spacer System
11. Solta Medical, Inc. Announces Second Quarter 2010 Results Release Date and Conference Call
Post Your Comments:
(Date:12/1/2015)... , Dec. 2, 2015  A combination of detailed ... the first time in the surgical planning for separation of ... annual meeting of the Radiological Society of North ... --> Conjoined twins, or twins whose bodies are connected, ... rates are low and separating them through surgery is extremely ...
(Date:12/1/2015)... , Dec. 1, 2015  A large study ... drug tamoxifen while taking an antidepressant found no increased ... today in The Journal of the National Cancer Institute. ... Tamoxifen is a commonly prescribed generic drug taken by ... developing a recurrence. Tamoxifen is recommended for five years, ...
(Date:12/1/2015)... Wash. and VANCOUVER , ... Committee (DMC) meeting, OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ... is continuing based on the pre-planned interim futility analysis ... review, no new safety issues were identified by the ... all analyses and final results are expected in the ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... ... and hematology continuing medical education (CME), today announced that the first annual School ... New York. , “The prevention, detection and treatment of gastrointestinal cancers are undergoing ...
(Date:12/1/2015)... , ... December 01, 2015 , ... Growth in medical ... due to decreases in utilization of hospital and nonhospital care, according to a recent ... Medical Benchmarks for Louisiana, 16th Edition , found medical payments per claim with more ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... images have been lifted as IMAGE Information Systems launches MED-TAB™ -- the world’s ... America Annual Meeting from November 29 to December 4, 2015. , MED-TAB ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has ... the Radiological Society of North America (RSNA) 2015 annual meeting through December 3 ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... clinical solutions for the care management and population health arenas, is pleased to ... clinical and cost containment services, has successfully implemented the ACUITY Complete Care™ Management ...
Breaking Medicine News(10 mins):